Phaseline

Companies › BioMendics

BioMendics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TolaSure Topical Gel
Topical agent targeting aggregated mutant keratin
KRT5Phase 2Epidermolysis Bullosa SimplexJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07027345TolaSure Topical GelPhase 2Epidermolysis Bullosa SimplexOtherJan 2027

Targets

KRT5 (1)

Companies with the same targets

–

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.